Advertisement
Singapore markets open in 1 hour 14 minutes

  • Straits Times Index

    3,293.13
    +20.41 (+0.62%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • Dow

    38,460.92
    -42.77 (-0.11%)
     

  • Nasdaq

    15,712.75
    +16.11 (+0.10%)
     

  • Bitcoin USD

    64,226.86
    -2,199.72 (-3.31%)
     

  • CMC Crypto 200

    1,383.28
    -40.82 (-2.87%)
     

  • FTSE 100

    8,040.38
    -4.43 (-0.06%)
     

  • Gold

    2,328.70
    -9.70 (-0.41%)
     

  • Crude Oil

    82.82
    +0.01 (+0.01%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • Nikkei

    38,460.08
    +907.92 (+2.42%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • FTSE Bursa Malaysia

    1,571.48
    +9.84 (+0.63%)
     

  • Jakarta Composite Index

    7,174.53
    -7,110.81 (-49.78%)
     

  • PSE Index

    6,572.75
    +65.95 (+1.01%)
     

Why GSK May Have Bet Too Big on a Pandemic Pipeline

Natalie Forbes, The Motley Fool
·4-min read
Why GSK May Have Bet Too Big on a Pandemic Pipeline

Pharmaceutical giant GlaxoSmithKline (NYSE: GSK) missed out on this early action and now looks to launch several pandemic products this year. GSK has three separate COVID vaccines in late-stage development, in various partnerships with Sanofi (NASDAQ: SNY), South Korean pharmaceutical SK bioscience, and Canadian biopharmaceutical Medicago. GSK's Phase 3 clinical trials are wrapping up, and GSK expects regulatory decisions in the US and EU starting later this year.

Continue reading